OR WAIT 15 SECS
The company will expand its clinical supply chain services by establishing two new facilities in Rheinfelden and Weil am Rhein, Germany.
Thermo Fisher Scientific announced on Dec. 15, 2020 that it will expand its clinical supply chain services by establishing two new facilities in Rheinfelden and Weil am Rhein, Germany.
The 86,000-ft2 Rheinfelden facility will increase the company’s capabilities for secondary packaging, storage, logistics, and distribution of clinical supplies by utilizing the new space as a strategic logistics hub for shipping by road or air, Thermo Fisher said in a company press release. Additionally, the 9600-ft2 Weil am Rhein site will offer ultra-low-temperature, cryogenic storage and cold chain expertise for cell and gene-based therapies, including COVID-19 vaccine candidates, via -80 °C freezers, liquid nitrogen cryogenic storage tanks, and walk-in 2-8 °C and -20 °C cold storage technology.
The Rheinfelden site is set to open in late December 2020, while the Rhein site will open in January 2021, according to the company press release.
"With today's complex and changing landscape, assurance of clinical trial supplies has never been more critical," said Mike Shafer, senior vice president and president, pharma services, Thermo Fisher Scientific, in the press release. "These facilities combined with our established regulatory expertise will give customers the continuity and in-region capabilities to support clinical trials across multiple therapy areas. Ultimately, we are enabling our customers to make the world healthier by bringing new medicines to patients with exceptional speed, efficiency, and quality."
Source: Thermo Fisher